Complex Generics And Biosimilars Drive First-Half Growth For Stada
As CEO Goldschmidt Acknowledges Company Owners Are Still Considering Options
Stada delivered solid growth in the first half of 2024, with complex generics launches and an increasingly prominent biosimilars business enabling two of its three operating divisions to report double-digit sales increases. Meanwhile, management also addressed persistent rumors of a possible sale by Stada’s owners.
